| First Author | Shin JH | Year | 2011 |
| Journal | Cell | Volume | 144 |
| Issue | 5 | Pages | 689-702 |
| PubMed ID | 21376232 | Mgi Jnum | J:171058 |
| Mgi Id | MGI:4948386 | Doi | 10.1016/j.cell.2011.02.010 |
| Citation | Shin JH, et al. (2011) PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 144(5):689-702 |
| abstractText | A hallmark of Parkinson's disease (PD) is the preferential loss of substantia nigra dopamine neurons. Here, we identify a new parkin interacting substrate, PARIS (ZNF746), whose levels are regulated by the ubiquitin proteasome system via binding to and ubiquitination by the E3 ubiquitin ligase, parkin. PARIS is a KRAB and zinc finger protein that accumulates in models of parkin inactivation and in human PD brain. PARIS represses the expression of the transcriptional coactivator, PGC-1alpha and the PGC-1alpha target gene, NRF-1 by binding to insulin response sequences in the PGC-1alpha promoter. Conditional knockout of parkin in adult animals leads to progressive loss of dopamine (DA) neurons in a PARIS-dependent manner. Moreover, overexpression of PARIS leads to the selective loss of DA neurons in the substantia nigra, and this is reversed by either parkin or PGC-1alpha coexpression. The identification of PARIS provides a molecular mechanism for neurodegeneration due to parkin inactivation. |
